Pablo Corral on Lipid-Lowering Therapy and Cognition: Evidence vs Myth
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Lipid-Lowering Therapy and Cognition: Evidence vs Myth
1. Elevated LDL-C remains the leading modifiable risk factor for cardiovascular disease and a major contributor to global mortality.
2. Concerns about cognitive adverse effects of lipid-lowering therapies (LLTs), particularly statins, are largely driven by early case reports rather than robust clinical evidence.
3. Observational studies and randomized trials consistently show no significant association between statin use and cognitive decline, with some data suggesting potential protective effects against dementia.
4. Major randomized trials (HPS, PROSPER, HOPE-3) found no difference in cognitive outcomes between statin-treated and placebo groups.
5. PCSK9 inhibitors (evolocumab, alirocumab) demonstrate neurocognitive safety, even with very low LDL-C levels and long-term exposure.
6. Ezetimibe and bempedoic acid show neutral neurocognitive profiles, with emerging signals of possible neuroprotective effects.
Current data support a clear conclusion:
- Lowering LDL-C improves cardiovascular outcomes without meaningful cognitive harm.
- The real knowledge gap is not safety, but understanding whether lipid-lowering therapies might also confer long-term neuroprotection.
Take-home message:
Fear of cognitive decline should not justify therapeutic inertia.
The price of untreated LDL-C is cardiovascular disease—not cognitive impairment.”
Read the full article here.
Article: Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
Authors: Raiza Rossi, Armin Nouri, Zafer Akman, Shefa Arya Nezhad, Abdulla A. Damluji, Michael G. Nanna
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation